Insider Sell: EVP Wendy Carruthers Sells 6,983 Shares of Boston Scientific Corp (BSX)
Boston Scientific Corporation is a global medical technology company that develops, manufactures, and markets a broad range of medical devices used in various interventional medical specialties, including interventional cardiology, peripheral interventions, cardiac rhythm management, electrophysiology, endoscopy, urology, pelvic health, and neuromodulation.According to a recent SEC Filing, Wendy Carruthers, EVP, Human Resources at Boston Scientific Corp (BSX), sold 6,983 shares of the company on February 23, 2024. Over the past year, the insider has sold a total of 123,694 shares and has not made any purchases.
The insider transaction history for Boston Scientific Corp shows a pattern of insider selling, with 39 insider sells and no insider buys over the past year.On the valuation front, shares of Boston Scientific Corp were trading at $66.89 on the day of the insider's recent transaction, resulting in a market cap of $97.811 billion. The price-earnings ratio stands at 62.31, which is above the industry median of 27.635 but below the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio is 1.24, indicating that Boston Scientific Corp is considered modestly overvalued based on its GF Value of $54.10. The GF Value is an intrinsic value estimate that takes into account historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
